Literature DB >> 25430505

A prospective study of erectile function after transrectal ultrasonography-guided prostate biopsy.

Katie S Murray1, Jason Bailey2, Keegan Zuk3, Ernesto Lopez-Corona4, J Brantley Thrasher1,4.   

Abstract

OBJECTIVE: To prospectively evaluate the effect of transrectal ultrasonography (TRUS)-guided prostate biopsy on erectile and voiding function at multiple time-points after biopsy. PATIENTS AND METHODS: All men who underwent TRUS-guided prostate biopsy completed a five-item version of the International Index of Erectile Function (IIEF-5) and the International Prostate Symptom Score (IPSS) before and at 1, 4 and 12 weeks after TRUS-guided biopsy. Statistical analyses used were a general descriptive analysis, continuous variables using a t-test and categorical data using chi-square analysis. A paired t-test was used to compare each patient's baseline score to their own follow-up survey scores.
RESULTS: In all, 220 patients were enrolled with a mean age of 64.1 years and PSA level of 6.7 ng/dL. At initial presentation, 38.6% reported no erectile dysfunction (ED), 22.3% mild ED, 15.5% mild-to-moderate ED, 10% moderate ED, and 13.6% severe ED. On paired t-test there was a statistically significant reduction in IIEF-5 score at 1 week after biopsy compared with before biopsy (18.2 vs 15.5; P < 0.001). This remained significantly reduced at 4 (18.4 vs 17.3; P = 0.008) and 12 weeks (18.4 vs 16.9, P = 0.004) after biopsy.
CONCLUSIONS: The effects of TRUS-guided prostate biopsy on erectile function have probably been underestimated. It is important to be aware of these transient effects so patients can be appropriately counselled. The exact cause of this effect is yet to be determined.
© 2014 The Authors BJU International © 2014 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  erectile dysfunction; prostate biopsy; urinary symptoms

Mesh:

Year:  2015        PMID: 25430505     DOI: 10.1111/bju.13002

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

1.  Transperineal prostate biopsies for diagnosis of prostate cancer are well tolerated: a prospective study using patient-reported outcome measures.

Authors:  Karan Wadhwa; Lina Carmona-Echeveria; Timur Kuru; Gabriele Gaziev; Eva Serrao; Deepak Parashar; Julia Frey; Ivailo Dimov; Jonas Seidenader; Pete Acher; Gordon Muir; Andrew Doble; Vincent Gnanapragasam; Boris Hadaschik; Christof Kastner
Journal:  Asian J Androl       Date:  2017 Jan-Feb       Impact factor: 3.285

2.  Global Research Trends on Prostate Diseases and Erectile Dysfunction: A Bibliometric and Visualized Study.

Authors:  Chengquan Ma; Hao Su; Hongjun Li
Journal:  Front Oncol       Date:  2021-02-12       Impact factor: 6.244

3.  Perceived barriers to the adoption of active surveillance in low-risk prostate cancer: a qualitative analysis of community and academic urologists.

Authors:  Shellie D Ellis; Soohyun Hwang; Emily Morrow; Kim S Kimminau; Kelly Goonan; Laurie Petty; Edward Ellerbeck; J Brantley Thrasher
Journal:  BMC Cancer       Date:  2021-05-31       Impact factor: 4.430

4.  Atypical Small Acinar Proliferation: Repeat Biopsy and Detection of High Grade Prostate Cancer.

Authors:  Andrew Leone; Katherine Rotker; Christi Butler; Anthony Mega; Jianhong Li; Ali Amin; Stephen F Schiff; Gyan Pareek; Dragan Golijanin; Joseph F Renzulli
Journal:  Prostate Cancer       Date:  2015-09-14

5.  What should be done to minimize pain without any sexual function deterioration in transrectal prostate biopsy?

Authors:  Mehmet Giray Sönmez; Betül Kozanhan; Erhan Demirelli; Leyla Öztürk Sönmez; Cengiz Kara
Journal:  Cent European J Urol       Date:  2017-10-09

6.  Imaging of clinically silent rectoprostatic hematoma in MRI guided in-bore prostate biopsy.

Authors:  Marietta Garmer; Christin Hoffmann; Dietrich Grönemeyer; Birgit Wagener; Lars Kamper; Patrick Haage
Journal:  Sci Rep       Date:  2022-02-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.